$CBDW

1606 CORP. (CBDW): Entry into a Material Definitive Agreement

1606 CORP. (CBDW) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. cbdw_8k.htm 0001877461 false 0001877461 2026-07-22 2026-07-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (

Original reporting
Published Jul 24, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 24, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CBDW
Neutral
medium confidence
Mentioned
$CBDW
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CBDWNeutralMed
01

Why it matters

Extending maturity and revising conversion provisions can change the expected path of debt repayment versus equity issuance. The 50% discount and holder-at-option conversion can increase dilution over time, but the beneficial ownership cap limits immediate conversion beyond 9.99% (with a delayed step-up mechanism).

02

Market read

This 8-K is a capital-structure update that can affect CBDW’s dilution expectations through discounted, holder-controlled conversion mechanics.

03

What to watch

Traders should assess the current common stock liquidity and bid dynamics because the conversion price is tied to the closing bid on the conversion date, and the 61-day notice mechanism could delay any step-up in the ownership limit.

Relevance 6/10Novelty 6/10Timing: after-hours SEC 8-K filed July 24, 2026, covering events dated July 22, 2026

Background

The company previously issued an amended and restated promissory note to its former CEO, later amended again via a June 9, 2026 addendum approved July 22, 2026.

Company-level read

Ticker impact

$CBDWNeutralMedium confidence
Context

1606 Corp. amended its promissory note to extend maturity to Dec. 31, 2026 and expand a 50% discounted, holder-at-option conversion into common stock.

Expected impact

Near-term pressure possible if traders price in incremental dilution; direction depends on whether conversion is likely before the maturity extension and on current bid/discount economics.

Evidence & confidence

The filing discloses a specific change to conversion terms (50% discount to closing bid) and maturity extension, both of which can affect equity valuation through dilution expectations. However, the note is held by a former CEO and the filing does not quantify conversion likelihood or expected share issuance.

Market effects

Microcap/small-cap issuers may face heightened scrutiny when debt is amended to include discounted, holder-at-option equity conversion features.

No clear regional spillover indicated; impact is company-specific.

Limited global relevance; primarily affects CBDW’s capital structure and trading sentiment.

Counterpoint

The addendum may be largely administrative, with conversion constrained by the 9.99% beneficial ownership cap, reducing immediate dilution risk.

Key entities

  • 1606 Corp.

    Nevada corporation that approved an addendum to its promissory note, extending maturity and revising conversion terms.

  • Gregory Lambrecht

    Former CEO and director, holder of the promissory note whose conversion rights were amended.

  • Venu Aravamudan

    Board member who resigned effective July 21, 2026; vacancy left unfilled.

Related articles

$XFORMed

X4 Strengthens Cash Position Ahead Of Key Phase 3 Milestones

X4 Pharmaceuticals (XFOR) secured a $150M senior secured debt facility from K2 HealthVentures, replacing its previous loan. The initial $80M tranche was used to repay existing debt, with an additional $70M available. The company aims to advance mavorixafor (XOLREMDI) for chronic neutropenia, with Phase 3 trial results expected in 2028. XFOR stock closed at $2.81, up 1.44%.